Increased risk of advanced prostate cancer associated with MnSOD Ala-9-Val gene polymorphism

Kucukgergin C. , Sanli O., Tefik T. , Aydin M., Ozcan F. , Seckin S.

MOLECULAR BIOLOGY REPORTS, vol.39, no.1, pp.193-198, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 1
  • Publication Date: 2012
  • Doi Number: 10.1007/s11033-011-0725-2
  • Page Numbers: pp.193-198


We aimed to investigate the association between manganese superoxide dismutase (MnSOD) Ala-9-Val gene polymorphism and the initiation and/or progression of prostate cancer (PCa) as well as to evaluate its potential interactions with advanced age and smoking status. MnSOD Ala-9-Val gene polymorphism was carried out in 134 (mean age 64.1 +/- A 7.48) PCa patients and 159 (mean age 62.5 +/- A 7.53) healthy controls with serum prostate specific antigen (PSA) levels (< 4 ng/ml) and normal digital rectal examination (DRE) findings in this prospectively designed study. PCa patients were classified as low stage disease (T-1 or T-2 and N0M0 stages) and high stage disease (T-3 or T-4 and N0M0 or N-1 or M-1 stages). Genotypes for MnSOD Ala-9-Val gene polymorphism were identified by using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFPL). Despite lack of association between different genotypes of MnSOD Ala-9-Val gene polymorphism and the presence of PCa, patients with Ala/Ala genotype were at an increased risk of high stage disease compared with those with the Val/Val genotype [odds ratio (OR), 3.77; 95% CI, 1.30-10.94; P = 0.012]. However, no significant difference was observed in the distribution of each genotype among PCa patients, with respect to tumor grade. On the other hand, smoking status and aging did not seem to change the association between genotypes and PCa risk. Ala/Ala genotype of MnSOD polymorphism may have an effect on adverse features of PCa such as high stage disease.